First Time Loading...

Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 27.575 EUR 2.51% Market Closed
Updated: Apr 27, 2024
Section:
 

Relative Value

The Relative Value of one BAYN stock under the Base Case scenario is 82.641 EUR. Compared to the current market price of 27.575 EUR, Bayer AG is Undervalued by 67%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAYN Relative Value
Base Case
82.641 EUR
Undervaluation 67%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.6
P/S
P/S
Price to Sales
0.6
vs History
98
vs Industry
82
Median 3Y
1
Median 5Y
1.1
Industry
2.3
Forward
0.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
40
Median 3Y
11.4
Median 5Y
11.4
Industry
22.2
Forward
5.1
More Details
5.3
P/OCF
P/OCF
Price to OCF
5.3
vs History
95
vs Industry
45
Median 3Y
9.4
Median 5Y
7.5
Industry
16.7
More Details
9.6
P/FCFE
P/FCFE
Price to FCFE
9.6
vs History
49
vs Industry
30
Median 3Y
11.3
Median 5Y
9.3
Industry
22.6
More Details
0.8
P/B
P/B
Price to Book Value
0.8
vs History
98
vs Industry
66
Median 3Y
1.4
Median 5Y
1.3
Industry
2
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
98
vs Industry
69
Median 3Y
1.6
Median 5Y
1.7
Industry
2.5
Forward
1.1
More Details
2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2
vs History
98
vs Industry
72
Median 3Y
2.7
Median 5Y
2.9
Industry
5
More Details
3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3
vs History
84
vs Industry
49
Median 3Y
6.5
Median 5Y
6.9
Industry
13.2
Forward
5.2
More Details
6.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6.5
vs History
63
vs Industry
43
Median 3Y
10.4
Median 5Y
10.4
Industry
16.5
Forward
8
More Details
10.7
EV/OCF
EV/OCF
Enterprise Value to OCF
10.7
vs History
79
vs Industry
36
Median 3Y
14.8
Median 5Y
11.5
Industry
15.5
More Details
23
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
23
vs History
30
vs Industry
19
Median 3Y
19.1
Median 5Y
17.9
Industry
17.2
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
98
vs Industry
73
Median 3Y
0.7
Median 5Y
0.7
Industry
1.9
More Details

Multiples Across Competitors

BAYN Competitors Multiples
Bayer AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DE
Bayer AG
XETRA:BAYN
27.1B EUR 0.6 -9.2 3 6.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
696B USD 20.4 132.8 60 68.9
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 17 47.1 34.5 37.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
352.9B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
332.6B USD 5.5 911.2 45.2 88.3
UK
AstraZeneca PLC
LSE:AZN
185.5B GBP 5.1 39 141 226.2
CH
Novartis AG
SIX:NOVN
183.1B CHF 4.3 13.5 9.9 16.3
CH
Roche Holding AG
SIX:ROG
176.4B CHF 3 15.3 8.5 10
P/E Multiple
Earnings Growth
DE
Bayer AG
XETRA:BAYN
Average P/E: 1 362.7
Negative Multiple: -9.2 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
132.8
346%
DK
Novo Nordisk A/S
CSE:NOVO B
47.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
9 733.7
-24%
US
Johnson & Johnson
NYSE:JNJ
8.7
-20%
US
Merck & Co Inc
NYSE:MRK
911.2
7 454%
UK
AstraZeneca PLC
LSE:AZN
39
168%
CH
Novartis AG
SIX:NOVN
13.5
15%
CH
Roche Holding AG
SIX:ROG
15.3
26%

See Also

Summary
BAYN intrinsic value, competitors valuation, and company profile.
DCF Valuation
BAYN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BAYN stock valuation using valuation multiples.
Wall Street Estimates
BAYN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BAYN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 131,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.